@Article{096504020X15965357399750,
AUTHOR = {Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis},
TITLE = {Outcomes of Patients With Acute Myeloid Leukemia Who Relapse  After 5 Years of Complete Remission},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {7-8},
PAGES = {811--814},
URL = {http://www.techscience.com/or/v28n7-8/48470},
ISSN = {1555-3906},
ABSTRACT = {Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute 
myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our 
institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with 
late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At 
relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML 
relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents 
with an overall CR rate of 66%. The median time to relapse after achieving second CR (CR2) was 16.5 months 
[95% confidence interval (CI): 9.4, NA]. The median overall survival after first relapse was 28.6 months (95% 
CI: 7.3, 3.4–66.5 months). Despite initial CR after reinduction therapy, relapse rates are still high, suggesting 
that alternative strategies for postremission therapies are warranted in CR2. These approaches include the use 
of allogeneic hematogenic cell transplantation and the use of newly approved AML agents as maintenance 
therapy in nontransplant eligible patients.},
DOI = {10.3727/096504020X15965357399750}
}